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Abstract
Introduction—The use of hormonal contraception (HC) is increasing in HIV-infected women. Both
HC and HIV infection have been associated with adverse metabolic outcomes. We investigated the
association of progestin-only and combined (estrogen/progestin) HC with disorders of glucose and
lipid metabolism in HIV-infected and uninfected women.
Methods—Linear mixed models evaluated the association of HC type with fasting HDL, LDL,
triglycerides, the homeostasis model assessment estimate of insulin resistance (HOMA-IR), and
glucose in 885 HIV-infected and 408 HIV-uninfected women from the Women's Interagency HIV
Study seen between October 2000 and September 2005.
Results—Compared to non-HC users, progestin-only HC was independently associated with lower
HDL (-3mg/dL;95% confidence interval[CI]:-5,-1 in HIV-infected and -6mg/dL;95% CI:-9,-3 in
HIV-uninfected women), greater HOMA (+0.86;95% CI:0.51,1.22 and +0.56;95% CI:0.12,1.01).
Combined HC was associated with higher HDL(+5mg/dL;95% CI:2,7 and +5mg/dL;95% CI:3,7).
Conclusion—Progestin–only HC is associated with lower HDL and greater HOMA-IR than non-
HC users. Combined HC may be preferred in HIV-infected women of reproductive age at risk for
cardiovascular disease, but interactions with antiretroviral therapy that may impair contraceptive
efficacy have been reported. Alternative HC methods that minimize adverse outcomes but maintain
efficacy require further study.
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Introduction
Hormonal contraception (HC) is an issue of growing importance to HIV-infected women, most
of whom are of reproductive age.1 In the US, most HIV-infected individuals younger than 25
years of age are women,2 and the prevalence of HIV infection among women in this age group
is increasing.2 Therefore, availability of effective, reversible birth control is crucial. While
barrier contraception is central to the prevention of HIV transmission, these methods are less
effective as contraceptives, having higher failure rates than, for example, intrauterine devices
or hormonal contraceptives.3
In the general population, hormonal contraceptive use has been associated with an increased
risk of metabolic dysregulation, especially lower serum high density lipoprotein (HDL)
concentrations, hypertriglyceridemia, insulin resistance, and elevated serum glucose
concentrations.4-6 HIV disease has been associated with a similar pattern of metabolic
dysregulation, and specific antiretroviral drugs may further worsen hypertriglyceridemia,
insulin resistance, and glucose tolerance. HC may thus represent an additional risk factor for
metabolic dysfunction in HIV-infected women.7 However, few if any studies have explored
the impact of HC on metabolic outcomes in the context of HIV infection.
The aim of our study was to investigate the association of progestin-only HC (depot
medroxyprogesterone acetate (DMPA), levonorgestrel implants) and combined HC (pill or
patch containing estrogen and progestin) with disorders of glucose and lipid metabolism in an
ethnically diverse cohort of HIV-infected and uninfected women. The outcomes of interest
included fasting HDL, low density lipoprotein (LDL), HDL, triglycerides, glucose and insulin
resistance as estimated by HOMA-IR.
Methods
Study population
Participants were HIV-infected and uninfected women enrolled in the Women's Interagency
HIV Study (WIHS), an ongoing multicenter longitudinal cohort study of the progression of
HIV infection in women. A total of 3766 women (2791 HIV-infected and 975 HIV-uninfected)
were enrolled in either 1994-5 (n=2623) or 2001-2 (n=1143) from six sites: Bronx/Manhattan,
Brooklyn, Washington D.C., Chicago, Los Angeles, and the San Francisco Bay Area. The
seropositive cohort reflected the characteristics of the HIV/AIDS epidemic in US women.8
The HIV-uninfected women were similar to the HIV-infected women in sociodemographic
characteristics and HIV risk factors. The recruitment methods and baseline characteristics of
enrollees have been reported elsewhere.8, 9 Institutional review boards approved all protocols
and informed consent forms, which were completed by all study participants. A structured
interview, physical examination, and the collection of blood, urine, and cervicovaginal fluid
samples were performed at each semiannual visit.
Beginning in October 2000, serum specimens for glucose, insulin, and lipids were collected
after at least an 8-hour fast. This analysis reports on 875 HIV-infected and 406 HIV-uninfected
women with fasting glucose, insulin, and lipid data available on at least one visit between
October 2000 and September 2005 who met the following study criteria: 1) between the ages
of 18 and 52 years and reported being post-menarchal and premenopausal for the duration of
the study; 2) did not self-report a history of hysterectomy; and 3) did not have diabetes (i.e.
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did not have a fasting plasma glucose greater than 125 mg/dL, report a diagnosis of diabetes,
or report antidiabetic medication use). Women who met criteria for diabetes during follow up,
were excluded from analysis beginning with the first visit diabetes was diagnosed. Women
who became pregnant during follow-up (n=22) were excluded for the duration of the pregnancy
and were then reincorporated into the study at their first post-delivery semiannual study visit.
Among the 22 women who became pregnant, 34 pregnancies were reported (29 among HIV-
uninfected women, 5 among HIV-infected). Of these, 20 occurred within 6 months of reported
HC use (15 among HIV-uninfected women and 5 among HIV-infected).
Because the metabolic effects of combined estrogen and progestin contraceptives may differ
significantly from those of progestin-only methods, those women using combined HC were
evaluated separately from those using progestin-only HC. Both of these groups were compared
with women who either used non-HC or did not contracept. Women could contribute to more
than one contraceptive group during the course of the study as many of these women changed
contraceptive method over time. Twenty-two of the 113 women who reported using combined
HC at baseline remained on this method throughout the study period, as did 16 of the 133
women who reported using progestin-only HC at baseline. Forty-eight women changed HC
method over the course of the study, and some changed methods more than once. There were
22 changes from a progestin-only to a combined HC method, 17 from combined to progestin-
only HC, and 19 changes from one type of combined HC to another. The baseline visit for each
participant was the first visit for which fasting laboratory information was available.
Statistical analysis
Within HIV serostatus groups, the association between the variables of interest and
contraceptive use were compared and tested for statistical significance using a t-test for
continuous characteristics, and chi square or Fisher's exact test for categorical characteristics.
Variables with skewed distributions were normalized by transformation or categorized. The
Wilcoxon rank sum test and Fisher's exact test were used when non-normality persisted.
Variables that were not normally distributed were transformed, if possible. Among HIV-
uninfected women using progestin-only HC or comparators, triglycerides, HOMA, and glucose
were log transformed. For HIV-uninfected women using combined HC and comparators, BMI,
triglycerides, HOMA, glucose, and insulin were log transformed. Among HIV-infected
women, for those using progestin-only HC and comparators, HDL was square root
transformed, and triglycerides, LDL, waist circumference, hip circumference, glucose, and
HOMA were log transformed. For those using combined HC and comparators, HDL was square
root transformed, and triglycerides, HOMA, glucose, insulin, waist and hip circumference were
log transformed. Neither AST, ALT, nor HIV viral load could be normalized through
transformation for any of the applicable groups, thus all were categorized by interquartile
ranges. Among HIV-infected women using progestin-only HC and comparators, CD4 count
could also not be normalized through transformation, and interquartile ranges were used to
categorize this variable.
Random coefficient multivariable linear mixed regression models were used to identify factors
associated with HDL, LDL, triglycerides, HOMA-IR and glucose. HIV-infected and HIV-
uninfected women were analyzed separately, as were those who used progestin-only HC and
those using combined HC.
A review of the literature guided the selection of demographic and clinical covariates with
previously demonstrated independent effects on lipid, insulin, and glucose levels. Only those
covariates with a statistically significant (P≤0.05) unadjusted association with the outcome of
interest (i.e., HDL, LDL, triglycerides, HOMA-IR, and glucose) were included in the analysis.
Those variables that did not retain significance at the P<0.05 level in a multivariable model
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were removed by backwards selection. During model selection, parameter estimates were
obtained by maximum likelihood; parameter estimates in the final model were obtained by
restricted/residual maximum likelihood.
Missing data is one of the central problems in longitudinal research.10 We, therefore, used
multiple imputation11 via the SAS procedure MI. The percent of missing data ranged from less
than 1% to 38%. By using multiple imputation, we were able to include all observations in our
analysis. Imputation of the outcomes using the predictors under study minimizes bias in the
relationship between predictors and outcomes.12, 13
Ten imputed data sets were created using all the variables considered in these analyses.14 The
following variables were used to impute the missing data: time (visit), progestin-only
contraceptive use, HDL, LDL, triglycerides, HOMA-IR (or insulin in the glucose models),
glucose, aspartate aminotransferase, alanine aminotransferase, waist circumference, hip
circumference, HIV serostatus, age, race, education, employment, income, insurance, family
history of diabetes, use of medications for dyslipidemia, alcohol use, and marital status. Body
mass index was not included as it was less strongly associated with the outcomes of interest
than either waist or hip circumference. Analyses of the imputed data sets were combined using
Rubin's rule,15 as implemented in the SAS procedure MIANALYZE.
Subgroup analysis
A subgroup analysis was conducted in HIV-infected women to evaluate the role of HIV-
specific factors including CD4 count, HIV viral load, and antiretroviral therapy use (defined
as current use of nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse
transcriptase inhibitors (NNRTI), and/or protease inhibitors (PI)) on the relationship between
HC and lipid levels, HOMA-IR, and glucose.16 The same approaches to missing data and model
building were used as described above. SAS version 9.1 was used for all statistical analyses.
Results
Among the HIV-infected and uninfected women included in the analysis, those who used HC
were younger than those who did not (Table 1). HIV-infected and HIV-uninfected women who
used combined HC were more likely to be white, and to be employed, and less likely to be
current smokers than women who used progestin-only HC or non-HC/no contraception.
Among HIV-uninfected women, those who used combined HC were more likely to be insured
than women who did not. Among HIV-infected women, those who used combined HC were
less likely than others to have a family history of cardiovascular disease and to be HCV
seropositive. The CD4 count at time of entry into the study among women who used combined
HC was higher than in those who used progestin-only HC or non-HC/no contraception. There
was little difference in the use of antiretroviral therapy (ART) by drug class among the three
contraceptive groups.
At baseline, HIV-infected as well as uninfected women who used progestin-only HC were
more likely to have serum HDL concentrations less than 40 mg/dL than women using other
forms of contraception (Table 2). In addition, among HIV-infected women, those using
progestin-only HC were more likely to have triglycerides greater than or equal to 200 mg/dL
than women using other forms of contraception. However, more than two-thirds of the women
in all of the contraceptive groups had serum triglyceride concentrations in the normal range.
There were no statistically significant differences in the percentages of women with abnormal
glucose, HOMA-IR, or LDL.
In the multivariable model controlling for other clinical and sociodemographic variables,
compared to women who did not contracept or who used non-HC, progestin-only HC was
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associated with lower HDL and higher HOMA-IR in HIV-infected and HIV-uninfected women
(Table 3). Combined HC was associated with higher HDL in HIV-infected and HIV-uninfected
women. The association of combined HC with HOMA-IR was not statistically significant in
either the HIV-infected or HIV-uninfected women. The association of combined and progestin
HC with triglycerides, LDL, and glucose was not statistically significant with the exception of
the small but statistically significant association of progestin HC use with lower glucose in
HIV-uninfected women.
We next examined the association of HC and changes over time in these metabolic outcomes.
In the multivariable models of the association of progestin-only HC, there was little change in
HDL over time among HIV-infected women (change in HDL per 6 month visit: 0.01 mg/dL;
95% CI: -0.16, 0.19 mg/dL; p=0.87). In HIV-uninfected women, there was a small but
statistically significant decrease in HDL over time (change in HDL per 6 month visit: -0.32
mg/dL; 95% CI: -0.59, -0.06 mg/dL; p=0.02). There was also little change in HOMA-IR over
time among both HIV-infected and uninfected women (change in HOMA-IR per 6 month visit:
-0.03; 95% CI: -0.06, 0.003; p=0.07; -0.02; 95% CI: -0.06, 0.02; p=0.32, respectively). In the
multivariable models examining the association of combined HC, there was no statistically
significant change in HDL over time, either among HIV-infected or HIV-uninfected women
(change in HDL per 6 month visit: -0.03 mg/dL; 95% CI: -0.27, 0.22 mg/dL; p=0.80; change
in HDL per 6 month visit:0.06 mg/dL; 95% CI: -0.12, 0.25 mg/dL; p=0.49, respectively).
Neither progestin-only nor combined HC was statistically significantly associated with serum
triglycerides, LDL or glucose in the longitudinal analyses (data not shown).
Among the HIV-infected women, addition of HIV-specific covariates to the multivariate model
strengthened the association between progestin-only HC and HDL (estimate remained
constant: -3 mg/dL per 6 month visit, p=0.021 to p=0.0052 after addition of HIV-specific
covariates), and HOMA-IR (estimate increased: 1.13 per 6 month visit to 1.15 per 6 month
visit, p<0.0001 for both). For the combined HC model, addition of HIV-specific covariates did
not strengthen the associations between combined HC and any of the metabolic outcomes (data
not shown).
The results using a complete-case analysis were similar, albeit less precise, to those presented
using multiple imputation.
Discussion
In our large cohort of ethnically diverse HIV-infected and uninfected women, we found that
progestin-only and combined HC impact metabolic outcomes differently. Progestin-only HC
was associated with lower HDL and greater HOMA-IR in HIV-infected and uninfected women.
On the other hand, combined HC was associated with higher HDL in HIV-infected and
uninfected women. Addition of HIV-specific variables strengthened the association between
progestin-only HC and lower HDL and higher HOMA-IR in HIV-infected women; the
association between combined HC and any of the metabolic outcomes was not altered.
Our findings that progestin-only HC was associated with lower HDL are consistent with
published studies in HIV-uninfected populations.17 18 19-22 While we noted that the HDL
trajectory decreased over time in HIV-uninfected women, in particular, the clinical significance
of the small, but significant six-month average decreases in HDL is unclear. Whether HDL
levels improve once HIV-infected women discontinue progestin-only HC or whether NNRTI
use (which has been associated with increased HDL23) might mitigate the negative effects of
progestin-only HC on HDL levels also needs to be studied.
It was not surprising that there was little difference in LDL between hormonal contraceptive
users and non-users. LDL is primarily influenced by the estrogen component in combined
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hormonal contraceptives and less by progestin,5 but even with combined hormonal
contraceptive use, alterations in LDL levels are often not seen. However, some studies indicate
that low-dose oral contraceptive pills are associated with increased proportions of small, dense
LDL subfractions, most likely because of the increase in TG levels.24 This change in the type
of LDL particle is concerning as the small, dense LDL subfractions are more easily oxidized
and thus more atherogenic than the normal LDL particles.
It was somewhat unexpected that serum triglyceride concentrations did not differ in HIV-
infected or uninfected women between progestin users and non-users as DMPA has been
associated with a mild increase in triglycerides in a prior study.25 Our sample size may have
been too small to detect a similar increase.
Progestin-only contraceptives such as DMPA and levonorgestrel implants have been
consistently associated with worsening insulin resistance19, 25-27 and with unfavorable
alterations in insulin metabolism in general,19-22 which are consistent with our findings. Some
authors have also shown that longer exposure to these progestin-only methods may lead to
more severe dysregulation of glucose levels and insulin responses.19, 20, 28 We were unable
to adequately assess the duration of exposure to HC with disorders in glucose metabolism
because of frequent changes in contraceptive methods and the small sample size. This study
should be re-evaluated with a larger sample size which might be available through
collaborations among HIV observational cohorts that collect contraceptive and metabolic data.
Patterns of contraceptive use should also be addressed to determine if frequent changes of
contraceptive methods are characteristic of other cohorts as well.
Glucose, on the other hand, has been found to be adversely affected by both combined hormonal
and progestin-only contraception. Formulations using higher doses of estrogen (50 mcg) have
a more negative impact on insulin action and glucose metabolism than formulations that use
lower doses of estrogen (20-35 mcg). With regards to the progestin component, Godsland and
colleagues,29 Wynn & Godsland,30 and Wynn and colleagues31 have consistently found that
levonorgestrel containing oral contraceptive pills, regardless of the dose, produce consistently
worse glucose outcomes than other progestins, even when controlling for estrogen dose. We
were not powered to explore the impact of specific estrogen/progestin combinations on glucose
outcomes in our study, thus the variety of progestins and estrogen doses used by study
participants may have masked the impact of any specific combination. Interestingly, among
HIV-uninfected women using progestin-only contraception, serum glucose levels were lower
than among non-progestin users; the clinical significance of this decrease is unclear.
Our findings are important because research in the general population has demonstrated that
the risk for metabolic dysfunction associated with HC use may be more pronounced in women
with additional risk factors for metabolic dysfunction, including race/ethnicity32 and past
medical history.33 Our study suggests that HIV infection is yet another of these additional risk
factors. Furthermore, HC is becoming more common among HIV-infected women. In a
retrospective cohort study of an urban clinic in New Orleans,34 Clark and colleagues found
that the use of DMPA in HIV-infected women increased from 9% between 1994-1996, to
almost 17% between 2000-2002. As larger numbers of HIV-infected women choose HC and
with the advent of newer progestin contraceptives, further study will be needed to evaluate the
impact of these contraceptives on metabolic parameters and long-term cardiovascular risk.
There are limitations to the present work. We assumed that the missing data were missing at
random, conditional on the set of measured variables included in this analysis. Given these
assumptions, we used multiple imputation, which allowed maximal use of the observed
information, to strengthen our results as opposed to using only those subjects with complete
data for the variables of interest.35 Confidence in our outcomes was reinforced by the fact that
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the complete-case analyses were not different from the imputed analyses. Because this is an
observational study, our results may be due to confounding by unmeasured factors. However,
the richness of the WIHS dataset allowed us to assess and control for a wide variety of
covariates that are commonly associated with metabolic outcomes. We were not able to
determine the association of the specific types of progestin-only HC with metabolic outcomes,
due to the small number of levonorgestrel implant users (n=3). We were also not able to assess
the effects of the different antiretroviral medications on metabolic parameters, relative to HC
type. Furthermore, while we observed that a small percentage of women became pregnant soon
after initiating HC, we were not able to assess whether this was due to lack of adherence or to
failure due to lower hormone levels. Further study is needed to determine whether
pharmacokinetic alterations in serum contraceptive hormone levels (due to a possible
interaction with antiretroviral therapy) is associated with contraceptive failure and increased
unplanned pregnancies. Even though the WIHS with its large, ethnically diverse sample of
women was the ideal cohort for this study, data on duration of HIV infection and duration of
ART use is limited, and the sample sizes for women using either progestin-only or combined
HC were small. Combining a variety of cohorts that collect this information on women would
provide one option for further pursuing these studies.
Despite these study limitations, the longitudinal study design enabled us to assess the outcome
trajectories over time in the context of the predictor variable and the covariates, which provided
a stronger analysis than would have been possible with a cross-sectional design.
In conclusion, progestin-only HC is associated with negative metabolic outcomes in
reproductive age women. In HIV-infected women, adjustment for HIV-related factors
strengthened these negative associations, suggesting that progestin-only HC should be used
with caution in HIV-infected women at risk for cardiovascular disease. Combined HC may be
preferable in terms of metabolic risk, but interactions with both NNRTIs and PIs have been
reported that may impair contraceptive efficacy.36 Further research is needed to elucidate the
mechanism by which HC might impact metabolic outcomes in HIV-infected women, and
whether newer, alternative HC methods, such as the levonorgestrel intrauterine device, might
be preferable, as it appears to exert its effect locally. HIV-infected women and their health care
providers need to be aware of possible side effects of the different contraceptive formulations
so that informed contraceptive choices can be made and appropriate follow-up care provided.
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